As of 8:00 a.m. EDT / 3:00 p.m. Türkiye time on October 9, 2026. This brief reviews developments from October 8 through October 9.

Yıldız Holding's due diligence process for the U.S. snack brand acquisition is reported to be progressing on schedule, with the financial, legal, and operational workstreams all in progress. The company has engaged a major U.S. investment bank as financial advisor and a leading U.S. law firm as legal counsel for the transaction.

Key due diligence focus areas include: the target's retail distribution agreements and the terms under which they can be assigned or novated following a change of control; the target's co-manufacturing arrangements and the capacity and quality implications of transitioning production to Yıldız's manufacturing network; the target's brand licensing and trademark portfolio; and the target's U.S. workforce, including any collective bargaining agreements and key employee retention arrangements.

The HSR Act filing is expected to be made within the next two weeks, triggering the 30-day initial waiting period. If the DOJ or FTC issues a second request, the waiting period will be extended significantly. Given the relatively modest market shares of both Yıldız and the target in the U.S. snack market, a second request is considered unlikely.

Warburg Pincus announced the completion of the first phase of its PantherX Rare integration on October 8, including the appointment of a new Chief Commercial Officer with specialty pharmacy experience, the launch of a patient access program expansion initiative, and the initiation of a technology investment program to enhance PantherX's patient support platform.

The patient access program expansion is a critical strategic priority for PantherX: rare disease specialty pharmacies derive significant competitive advantage from their ability to navigate complex payer authorization processes and provide comprehensive patient support services. Warburg Pincus's investment in expanding PantherX's patient access capabilities reflects the importance of these services in the rare disease pharmacy market.

Lone Star Funds announced the first add-on acquisition for its ContiTech platform on October 8. The target, a U.S.-based manufacturer of specialty industrial hoses for the oil and gas market, was acquired for approximately $85 million. The acquisition adds U.S. manufacturing capacity and oil and gas market exposure to ContiTech's existing global industrial hose business.

The Yıldız Holding due diligence progress confirms that the transaction is on track for a Q4 2026 definitive agreement. The Warburg Pincus–PantherX and Lone Star–ContiTech post-closing activities reflect the active integration and add-on acquisition strategies of their respective private equity sponsors.

This publication is for general informational purposes only and does not constitute legal advice.